2016
A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer
Hadad SM, Jordan LB, Roy PG, Purdie CA, Iwamoto T, Pusztai L, Moulder-Thompson SL, Thompson AM. A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer. BMC Cancer 2016, 16: 745. PMID: 27658825, PMCID: PMC5034430, DOI: 10.1186/s12885-016-2788-x.Peer-Reviewed Original ResearchIngenuity Pathway AnalysisBreast cancerCore biopsyDrug therapyOperable breast cancerSequential core biopsiesUntreated breast cancerHormone receptor statusPrimary breast cancerPathway analysisPR immunohistochemistryUntreated patientsReceptor statusPrimary cancerNon-treatment controlBiomarker statusProspective comparisonBiomarker changesDrug interventionKi67 scoreBiopsyBiomarker effectsDrug efficacyKi67MRNA expression
2005
Pharmacogenomics and Clinical Biomarkers in Drug Discovery and Development
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Pharmacogenomics and Clinical Biomarkers in Drug Discovery and Development. American Journal Of Clinical Pathology 2005, 124: s29-s41. PMID: 16468416, DOI: 10.1309/xyqafanapync6x59.Peer-Reviewed Original ResearchConceptsHuman genome sequenceGene expression profilesGenome sequenceEpigenetic eventsExpression profilesProteomics researchDrug discoveryRapid evolutionComputational biologyPharmaceutical industryMolecular diagnosticsDiscoveryFurther understandingBiosensorRNABiologyAnticancerSequenceClinical biomarkersAnti-inflammatory drugsDrug efficacyToxicityPrediction of responseDevelopmentContinuous technological advancements